Bio-FD&C Co. Ltd. (251120) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Bio-FD&C Co. Ltd. stock KRW 15,158, price KRW 8,550, upside +77.3%, quality 75 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
56‑month range 7,090 KRW – 28,300 KRW · fair‑value band 9,318 KRW – 23,395 KRW · the 8,550 KRW price screens below the 15,158 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Bio-FD&C Co. in your weekly email
Every Wednesday you see whether Bio-FD&C Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea.
Show moreShow less
It offers plant cell, peptide, natural extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, acne, skin irritation, wound healing, scalp improvement, skin moisturizing, fine dust, hair loss improvement, pores, lifting, whitening, skin texture, anti-inflammation/skin soothing, and anti-oxidation.
The company was founded in 2005 and is headquartered in Incheon, South Korea.
Stock analysis
Bio-FD&C Co. Ltd. (251120) currently trades at 8,550 KRW, while our model-based Fair Value estimate is 15,158 KRW, implying the stock looks roughly 44% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 19,229 KRW per share, and 18 of the 24 models we run sit above the 8,550 KRW price.
Bear case: the Asset-Based group reads lowest at 6,390 KRW, and 6 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 9,318 KRW (bear) to 23,395 KRW (bull), the price of 8,550 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Bio-FD&C Co. Ltd. reported revenue of 19.2B KRW in FY2025 versus 12.0B KRW in FY2021, a compound +12.5%/yr. Reported net income was 6.7B KRW in FY2025, compounding +23.1%/yr from FY2021.
Key figures
Market cap 72.9B KRW (≈ $53.9M) Micro · P/E ratio 11.3 · P/S ratio 3.73 · EPS (TTM) 751.15 KRW · Net margin 32.8% · Return on equity 9.2% · Return on assets (EBIT) 9.1% (5-year average) · Operating margin 39.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 77%, 251120 screens cheaper than that median.
Fair Value models
Bear9,318 KRWFair Value 15,158 KRWBull23,395 KRW
Price 8,550 KRW · Upside +77.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (644.14 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+19.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.34% → 33%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−14.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −16.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 12/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside+77.3% · Top 25%
Profitability
Return on equity (12 months)9.2% · Top 25%
Return on assets9.1% · Top 25%
Net margin (12 months)32.8% · Top 25%
Operating margin (12 months)39.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)14.5% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bio-FD&C Co. Ltd. (251120) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 15,158 KRW versus a price of 8,550 KRW, about +77% upside (undervalued).
What is the fair value of 251120?
Our model-based fair value for Bio-FD&C Co. Ltd. is 15,158 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 8,550 KRW.
What is the quality score of 251120?
Bio-FD&C Co. Ltd. has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-FD&C Co. Ltd. (251120)?
Our model-based price target is the fair value of 15,158 KRW (as of Nov 9, 2026) from 24 valuation models. Cautious scenario 9,318 KRW, optimistic scenario 23,395 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-FD&C Co. Ltd. stock forecast for 2026?
Our models put fair value at 15,158 KRW, about +77% upside versus a price of 8,550 KRW (undervalued). Cautious scenario 9,318 KRW, optimistic scenario 23,395 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-FD&C Co. Ltd. (251120)?
Bio-FD&C Co. Ltd. reported trailing-twelve-month revenue of about 19.5B KRW (latest available figure, as of Nov 9, 2026).
What growth is priced into Bio-FD&C Co. Ltd. (251120)?
For today's price to be fair in a discounted-cash-flow model, Bio-FD&C Co. Ltd. would have to grow free cash flow by -14.9 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.3 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 251120 use?
Our models discount Bio-FD&C Co. Ltd. at 11.6 %: a base by market capitalisation (micro), damped by beta 0.36, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bio-FD&C Co. Ltd. that is -14.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Bio-FD&C Co. Ltd. (251120) delivered so far?
Over the past 5 years revenue at Bio-FD&C Co. Ltd. grew +17.3 % a year. The price currently implies free-cash-flow growth of -14.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bio-FD&C Co. Ltd. (251120) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Bio-FD&C Co. Ltd. (-14.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bio-FD&C Co. Ltd. (251120)?
The free-cash-flow yield on the price is 8.54 %: that much free cash flow Bio-FD&C Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bio-FD&C Co. Ltd. (251120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-FD&C Co. Ltd. it is 15,158 KRW per share (as of Nov 9, 2026), against a price of 8,550 KRW. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bio-FD&C Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 251120 trades below its calculated fair value: price 8,550 KRW, fair value 15,158 KRW, a gap of about +77% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 251120?
No. The price is what the market pays today (8,550 KRW); the fair value is what the company's own numbers justify (15,158 KRW). For Bio-FD&C Co. Ltd. the two are 6,608 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-FD&C Co. Ltd. worth?
The market values Bio-FD&C Co. Ltd. at about 72.9B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 8,550 KRW; our models calculate a fair value of 15,158 KRW per share.
What do the bullish and bearish scenarios say about 251120?
Our models span a range for Bio-FD&C Co. Ltd.: cautious scenario 9,318 KRW, base 15,158 KRW, optimistic 23,395 KRW per share (as of Nov 9, 2026, price 8,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 251120?
Bio-FD&C Co. Ltd. trades at a price-to-earnings ratio of 11.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 15,158 KRW is built from several models across several years. Other multiples: P/B 1.0, P/S 3.7, EV/EBITDA 8.3.
How solid is the balance sheet of Bio-FD&C Co. Ltd. (251120)?
Balance-sheet figures for Bio-FD&C Co. Ltd. (as of Nov 9, 2026): return on equity 9.2%. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is 251120 from its 52-week high?
Bio-FD&C Co. Ltd. trades at 8,550 KRW, about 49% below its 52-week high of 16,700 KRW and 21% above the low of 7,090 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 15,158 KRW is for.
Which stocks are comparable to Bio-FD&C Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-FD&C Co. Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 8,550 KRW, calculated fair value 15,158 KRW (+77%), Quality Score 75/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 251120 calculated?
We run Bio-FD&C Co. Ltd. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 15,158 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bio-FD&C Co. Ltd. currently trades 44% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-FD&C Co. Ltd. (251120)?
The closing price on Nov 6, 2026 was 8,550 KRW. Our model-based fair value is 15,158 KRW, about +77% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-FD&C Co. Ltd. right now?
The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (9,318 KRW). The market is more pessimistic than our downside scenario. A fairly wide model range (9,318 KRW to 23,395 KRW) leaves room in how you read the outcome.
Key figures of Bio-FD&C Co. Ltd.
How large is the market capitalisation of Bio-FD&C Co. Ltd. (251120)?
The market capitalisation of Bio-FD&C Co. Ltd. is 72.9B KRW (≈ $53.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-FD&C Co. Ltd. (251120)?
The price-to-sales ratio of Bio-FD&C Co. Ltd. is 3.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bio-FD&C Co. Ltd. (251120)?
Earnings per share at Bio-FD&C Co. Ltd. are 751.15 KRW (price ÷ EPS = P/E 11.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bio-FD&C Co. Ltd. (251120)?
The net margin of Bio-FD&C Co. Ltd. is 32.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-FD&C Co. Ltd. (251120)?
The return on equity (ROE) of Bio-FD&C Co. Ltd. is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-FD&C Co. Ltd. (251120)?
On an EBIT basis the return on assets of Bio-FD&C Co. Ltd. is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-FD&C Co. Ltd. (251120)?
The operating margin of Bio-FD&C Co. Ltd. is 39.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-FD&C Co. Ltd. (251120)?
Revenue at Bio-FD&C Co. Ltd. is growing +14.5% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bio-FD&C Co. Ltd. (251120)?
Earnings per share at Bio-FD&C Co. Ltd. are growing +11.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bio-FD&C Co. Ltd. (251120) carry?
The net debt of Bio-FD&C Co. Ltd. is 251M KRW (fiscal year 2020, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bio-FD&C Co. Ltd. in the live analysis
One click puts Bio-FD&C Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026